Compare

NAD+ vs Tirzepatide

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

NAD+

96 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 2% · Mixed 98% · Unfavorable overall 0%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Energy
197
Appetite
197

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Headache
66
Nausea
64
Injection site irritation
64

Self-reported dose per injection

Median bucket: 5+ mg · Most common: 5+ mg

Reports span 0.1 to ≥ 5 mg (open-ended top bucket)

0.1–0.2 mg
2
0.2–0.4 mg
17
0.4–0.6 mg
8
0.6–1 mg
1
1–2 mg
2
3–5 mg
2
5+ mg
165

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

How repeat users are trending

Among repeat reporters, 95% said they felt similar to their last entry, 5% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 51 days · Based on 42 repeat reporters

Tirzepatide

7 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 14% · Mixed 0% · Unfavorable overall 86%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Appetite
7
Sleep
1
Mood
1
Energy
1

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Nausea
3
Injection site irritation
3

Self-reported dose per injection

Median bucket: 5+ mg · Most common: 5+ mg

Reports span 0.4 to ≥ 5 mg (open-ended top bucket)

0.4–0.6 mg
1
5+ mg
6

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Sources (18)

Published sources linked on the NAD+ and Tirzepatide wiki pages.

  1. PubMed

    NAD+ metabolism and its roles in cellular processes during ageing

    Covarrubias AJ, Perrone R, Grozio A, et al. Nat Rev Mol Cell Biol. 2021

    Source
    Wiki study page →
  2. PubMed

    Safety and efficacy of NAD+ supplementation: a systematic review

    Reiten OK, Wilvang MA, Mitchell SJ, et al. J Clin Invest. 2021

    Source
    Wiki study page →
  3. PubMed

    NAD+ intermediates: The biology and therapeutic potential

    Yoshino J, Baur JA, Imai SI. Cell Metab. 2018

    Source
    Wiki study page →
  4. PubMed

    Nicotinamide Adenine Dinucleotide in Aging Biology: Potential Applications and Many Unknowns

    Bhasin S, Seals D, Migaud M, et al. Endocrine reviews. 2023

    Source
    Wiki study page →
  5. PubMed

    The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update

    Song Q, Zhou X, Xu K, et al. Advances in nutrition (Bethesda, Md.). 2023

    Source
    Wiki study page →
  6. FDA Drug Label

    MOUNJARO (tirzepatide) injection, for subcutaneous use - Prescribing Information

    Eli Lilly. FDA Drug Label. 2022

    Source
    Wiki study page →
  7. PubMed

    Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

    Jastreboff AM, Aronne LJ, Ahmad NN, et al. N Engl J Med. 2022

    Source
    Wiki study page →
  8. ClinicalTrials.gov

    Tirzepatide obesity studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  9. PubMed

    Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

    Frías JP, Davies MJ, Rosenstock J, et al. N Engl J Med. 2021

    Source
    Wiki study page →
  10. PubMed

    Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).

    Frias JP, De Block C, Brown K, et al. J Clin Endocrinol Metab. 2024

    Source
    Wiki study page →
  11. FDA Drug Label

    ZEPBOUND (tirzepatide) injection, for subcutaneous use - Prescribing Information

    Eli Lilly. FDA Drug Label. 2023

    Source
    Wiki study page →
  12. PubMed

    Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

    Garvey WT, Frias JP, Jastreboff AM, et al. Lancet (London, England). 2023

    Source
    Wiki study page →
  13. PubMed

    Tirzepatide for Obesity Treatment and Diabetes Prevention

    Jastreboff AM, le Roux CW, Stefanski A, et al. The New England journal of medicine. 2025

    Source
    Wiki study page →
  14. PubMed

    GLP-1 receptor agonist discontinuation and cardiovascular events and all-cause mortality in people with type 2 diabetes: a retrospective cohort study

    Ceriello A, Prattichizzo F, Lucisano G, et al. Lancet Reg Health Eur. 2026

    Source
    Wiki study page →
  15. PubMed

    Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial

    Aronne LJ, Ahmad NN, Fletcher M, et al. JAMA. 2024

    Source
    Wiki study page →